Can engineered blood cells fight cancer? early trial begins
NCT ID NCT07556653
First seen Apr 30, 2026 · Last updated Jun 22, 2026 · Updated 7 times
Summary
This early-phase trial tests a new treatment called WTX-212C, which uses engineered red blood cells to target advanced solid tumors. About 24 adults who have run out of standard options will receive the drug intravenously. The main goal is to check safety and find the right dose, not to cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WTX-212C (engineered red blood cells)
What this could lead to
If it works, this could point toward a new way to treat advanced solid tumors using engineered red blood cells.
What could go wrong
This is a very early, small trial focused on safety, not effectiveness. The treatment may not shrink tumors or could cause side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.